We provide a wide range of antibiotic susceptibility testing services such as Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) tests in accordance with the guidelines issued by the Clinical and Laboratory Standards Institute using broth micro dilution, broth macro-dilution, disk diffusion and agar dilution methods.
Minimum Inhibitory Concentration (MIC)
The MIC testing services for New Chemical Entity (NCE) helps determine the lowest concentration of an antimicrobial agent that prevents visible growth of a microorganism under defined test conditions.
We use the MIC values to evaluate the activity of new antimicrobial agents and to determine the NCE’s susceptibilities of microorganisms. MIC is considered as the ‘gold standard’ for determining the susceptibility of organisms to antimicrobials and is therefore used to judge the performance of all other methods of susceptibility testing.
Cultured microbes are incubated with the NCE at various concentrations and measured for the results using agar dilution or broth dilution methodology to determine the MIC endpoint. Agar dilution involves incorporating different concentrations of the antimicrobial substance into agar medium followed by the application of a standardized number of cells to the surface of the agar plate. For broth dilution, we often determine it in 96-well micro titer plate format, where microorganisms are inoculated into a liquid growth medium in the presence of different concentrations of an antimicrobial agent. Growth is assessed after incubation for a defined period of time (16–20 hours).
Susceptibility testing is typically conducted using organisms that contribute to an infectious process warranting antimicrobial chemotherapy. Several microorganisms such as aerobic or anaerobic bacteria, yeasts can be tested based on the requirement.
Minimum Bactericidal Concentration (MBC)
The MBC testing services help determine the lowest concentration of an antimicrobial agent required to achieve bactericidal killing defined at 99.9% reduction in the initial inoculum. We chose it by sub-culturing broth dilution concentrations that inhibit the growth of a bacterial organism i.e. concentrations at and above the MIC. The broth dilutions are streaked onto agar surface and incubated for 24 to 48 hours. MBC is the lowest broth dilution of antimicrobial that prevents the growth of the organism on the agar plate. Failure of the organism to grow on the agar plate implies that all viable microorganisms have been eliminated.
Why Aurigene Pharmaceutical Services?
Submissions to the US FDA
Highly- qualified and experienced scientists
Audited by the US FDA with zero 483 in 2019
BSL-2 compliant microbiology lab
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Microbiology Testing
Contact Us
Resources
JUNE 28, 2022
Neoantigen Specific T cells For Cancer Immunotherapy
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...
Read More
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...
Read More
Technology meets sustainability - How a complex API development process goes green
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...
Read MoreAlternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2023
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2021
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2021
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More -
Simple and efficient synthesis of imidazoquinoxalines and spiroquinoxalinones via pictect-spengler reaction using Wang resin, Synthetic Communications
2021
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.